Versant Capital Management Inc Acquires 743 Shares of Eli Lilly and Company $LLY

Versant Capital Management Inc lifted its position in Eli Lilly and Company (NYSE:LLY) by 49.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,260 shares of the company’s stock after buying an additional 743 shares during the quarter. Versant Capital Management Inc’s holdings in Eli Lilly and Company were worth $1,724,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the business. Sumitomo Mitsui Financial Group Inc. bought a new stake in shares of Eli Lilly and Company during the 2nd quarter worth $27,000. Evolution Wealth Management Inc. bought a new stake in Eli Lilly and Company in the second quarter valued at approximately $29,000. Steph & Co. boosted its position in Eli Lilly and Company by 290.0% during the 3rd quarter. Steph & Co. now owns 39 shares of the company’s stock valued at $30,000 after buying an additional 29 shares during the period. Financial Gravity Companies Inc. bought a new stake in shares of Eli Lilly and Company in the second quarter worth about $31,000. Finally, Bare Financial Services Inc grew its position in shares of Eli Lilly and Company by 263.6% in the 2nd quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock worth $31,000 after buying an additional 29 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on LLY shares. Daiwa America raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 16th. Scotiabank began coverage on shares of Eli Lilly and Company in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $1,165.00 target price on the stock. Berenberg Bank increased their price objective on Eli Lilly and Company from $830.00 to $950.00 and gave the company a “hold” rating in a research report on Tuesday, December 2nd. Sanford C. Bernstein reiterated an “outperform” rating on shares of Eli Lilly and Company in a research note on Friday, December 19th. Finally, BMO Capital Markets reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research report on Wednesday. Five research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $1,169.00.

Eli Lilly and Company Trading Down 0.4%

Shares of LLY opened at $1,073.10 on Thursday. The company’s fifty day moving average is $1,047.15 and its 200 day moving average is $867.23. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. The stock has a market capitalization of $1.01 trillion, a PE ratio of 52.50, a P/E/G ratio of 0.78 and a beta of 0.35. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. The company had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.Eli Lilly and Company’s revenue was up 53.9% on a year-over-year basis. During the same period last year, the company earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Sell-side analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, February 13th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is 29.35%.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: NVIDIA partnership: Lilly and NVIDIA announced a $1 billion AI co‑innovation lab to speed drug discovery, manufacturing and trials — a multi-year bet that could lower R&D costs and accelerate pipelines. Nvidia And Eli Lilly To Build $1 Billion AI-Powered Drug Discovery Lab
• Positive Sentiment: Pipeline & M&A: Lilly’s acquisition of Ventyx Biosciences has reassured investors worried about Wegovy competition and reinforces product/asset diversification beyond current injectables. Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns
• Positive Sentiment: Analyst support: BMO reiterated a Buy rating and $1,200 price target, citing Lilly’s leadership in incretin therapies and multi-therapy growth as durable drivers. Eli Lilly: Consolidating Incretin Leadership and Multitherapy Growth Supports Buy Rating
• Positive Sentiment: Promising new assets: Retatrutide (a next‑gen incretin) shows both strong weight‑loss potential and unexpected pain‑relief signals — a clinical upside that could materially expand indications and market value. Eli Lilly’s Most Promising Weight Loss Drug May Come With a Surprising Benefit: Pain Relief
• Neutral Sentiment: J.P. Morgan coverage & conference: JPM highlights obesity and GLP‑1 momentum; Lilly reported Q4 sales beats in context of the conference — positive fundamentals but already largely priced in. JPM26 Day 1: Obesity Front-and-Center, Q4 Sales Beats
• Neutral Sentiment: Momentum narrative: Market commentary notes LLY’s strong 2025 performance and momentum characteristics — supportive for sentiment but increases expectations. Why Eli Lilly Stock Gained 39.2% In 2025
• Negative Sentiment: Competitive threat: Several pieces raise the risk that Novo Nordisk’s oral GLP‑1 (Wegovy pill) could dent Lilly’s market share, prompting some investors to reassess growth durability. Can Novo Nordisk Unseat Eli Lilly as the Weight Loss Drug Leader in 2026?
• Negative Sentiment: Bear case pieces: Opinion articles argue switching to Novo or trimming LLY exposure given oral‑pill competition and valuation; these narratives can pressure shares despite fundamentals. Eli Lilly: Sell It And Buy Novo Nordisk Instead
• Negative Sentiment: Investor debate on trimming exposure: Columns asking “Is it time to dump shares?” highlight valuation and competitive risk; these pieces can weigh on intraday flows. Is It Time to Dump Your Shares of Eli Lilly?

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.